Apalutamide delays progression of nonmetastatic, castration-resistant prostate cancer

ScienceDaily | 2/8/2018 | Staff
normanorma (Posted by) Level 4
"Our study found that apalutamide treatment markedly improved metastasis-free survival and other clinical outcomes in men with castration-resistant prostate cancers and no detectable metastases," says Matthew Smith, MD, PhD, of the MGH Cancer Center, corresponding author of the NEJM report. "At this time, there are no approved treatments for men in that situation, so we need to wait until their disease progresses to add the standard therapies that have been approved for metastatic disease."

Senior author Eric Small, MD, deputy director of the Helen Diller Family Comprehensive Cancer Center at UCSF, who presented the data at the ASCO-GU Symposium, says, "This trial's results suggest that the availability of apalutamide should offer men with nonmetastatic, castration-resistant prostate cancer a treatment that can delay or prevent the development of metastases and other complications associated with disease progression."

Androgen-deprivation - Therapy - Removal - Testicles - Use

Androgen-deprivation therapy, either through surgical removal of the testicles or the use of drugs that suppress testosterone production, is standard treatment for men with metastatic prostate cancer and is also used for nonmetastatic cancer. Unfortunately, androgen deprivation stops working for almost all patients, leading to what is called castration-resistant disease. In such patients whose cancer has not yet spread, a rapid rise in prostate-specific antigen (PSA) levels warns of the near-term development of metastases, the major cause of complications and death from prostate cancer.

Apalutamide binds to the androgen receptor, blocking its activation by testosterone and other androgens. Apalutamide is...
(Excerpt) Read more at: ScienceDaily
Wake Up To Breaking News!
Homeschool or State Thought Police School, you choose.
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!